Acquisition Backing Aegerion Pharmaceuticals is now part of Amryt Pharma plc, indicating access to Amryt's broader rare disease portfolio and commercial infrastructure. This presents cross-sell opportunities for Amryt's existing and upcoming rare disease treatments to customers and partners previously engaged with Aegerion.

Rare Disease Focus Amryt's core emphasis on rare and orphan diseases suggests sales potential in niche specialty clinics and patient advocacy channels. Target opportunities include specialty distributors, direct-to-clinic outreach, and collaboration with centers of excellence that treat uncommon conditions.

Global Commercialization With Amryt described as having a growing commercial business and development pipeline, there is potential to expand market access, pricing, and reimbursement discussions across geographies where Amryt operates, leveraging existing channels for faster deployment of new therapies.

Strategic Partnerships Previous M&A activity and financing history (Chiesi acquisition, senior credit facilities) indicate a willingness to pursue strategic partnerships. Explore co-commercialization, licensing, or research collaborations with biotech firms, contract research organizations, and patient-focused organizations aligned with rare disease pipelines.

Digital & Data Enablement Amryt’s tech stack includes Salesforce, Adobe Experience Cloud, and other customer-facing tools, signaling readiness for data-driven sales and marketing initiatives. Propose targeted account-based marketing, digital engagement campaigns, and ecosystem partnerships to accelerate product adoption.